Organic Acids
Medchemexpress LLC Ela-32(human) (tfa) | 99.9% | 3967.82 | 1 MG
ELA-32(human) TFA is a potent, high affinity apelin receptor agonist with an IC50 of 0.27 nM and a Kd of 0.51 nM. This product does not bind to GPR15 and GPR25. It activates the PI3K/AKT pathway, promoting the self-renewal of hESCs via cell-cycle progression and protein translation. Additionally, it potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage, and stimulates angiogenesis in HUVEC cells.
- Potent, high affinity apelin receptor agonist
- IC50 of 0.27 nM and a Kd of 0.51 nM
- Exhibits no binding to GPR15 and GPR25
- Activates the PI3K/AKT pathway
- Promotes self-renewal of hESCs via cell-cycle progression and protein translation
- Potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage
- Stimulates angiogenesis in HUVEC cells
Medchemexpress LLC Sar441255 TFA | 99.9% | 4866.56 (free base) | 1 MG
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. It demonstrates high potency with balanced activation of all three target receptors. This compound shows positive acute glucoregulatory effects in diabetic obese monkeys, indicating its potential for metabolic and endocrine disease research, particularly in areas like obesity and type 2 diabetes.
- Potent unimolecular peptide receptor triagonist.
- Displays high potency with balanced activation of three target receptors.
- Shows positive acute glucoregulatory effects in diabetic obese monkeys.
- Relevant for research in metabolic diseases, including obesity and type 2 diabetes.
Medchemexpress LLC Hth-01-091 Tfa | 2000209-42-5 | 98.64% | 499.43 | 1 MG
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. It also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. This compound can be used for breast cancer research.
- Potent and selective MELK inhibitor.
- Inhibits multiple kinases including PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2.
- Suitable for breast cancer research.
Apexbio Technology LLC ENMD-2076 934353-76-1 50mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Medchemexpress LLC Benzoic acid (Standard) | 65-85-0 | 99.7% | 122.12 | 100 MG
Benzoic acid is an analytical standard intended for research and analytical applications. It is an aromatic alcohol naturally found in various plants and widely used as an additive in food, drinks, cosmetics, and other products, functioning as a preservative by inhibiting both bacteria and fungi.
- Analytical standard for research and analysis
- Naturally occurring aromatic alcohol
- Preservative action by inhibiting bacteria and fungi
- Commonly used in HPLC, GC, and MS experiments
Medchemexpress LLC L2P4 (TFA) | 98.3% | 1961.83 (free base) | 25 MG
L2P4 TFA is a peptide-based, EBNA1 targeting fluorescent probe that inhibits EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. It exhibits cytotoxicity in EBV-positive C666-1 cells with an LC50 of 46.4 μM.
- Peptide-based fluorescent probe
- Targets EBNA1
- Inhibits EBNA1 homodimer formation
- Selectively inhibits EBV+ tumor growth
- Exhibits cytotoxicity in EBV-positive C666-1 cells with an LC50 of 46.4 μM
- Relevant to peptide-drug conjugates (PDCs) and EBV research
- Related to antibody-drug conjugate/ADC and anti-infection pathways
Medchemexpress LLC SIAIS100 TFA | C46H51ClF5N9O7S | 25 MG
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader with a DC50 value of 2.7 nM. It is used for research into chronic myeloid leukemia (CML), exhibiting anti-proliferative activity against K562 cells with an IC50 value of 12 nM. This compound degrades BCR-ABL with high ratios at nanomolar concentrations and maintains a durable cellular response after drug removal.
- Potent BCR-ABL PROTAC degrader
- Used for chronic myeloid leukemia (CML) research
- Exhibits anti-proliferative activity against K562 cells
- Induces sustained and robust BCR-ABL degradation
- Degrades G250E/T315I mutation dose-dependently
C(O)=O | 100g | 490510430](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000161341.jpg-250.jpg)
eMolecules 79-33-4 | L-Lactic acid | Ambeed | MFCD00064266 | 90.078 | C3H6O3 | 85.000 | C[C@H](O)C(O)=O | 100g | 490510430
L-Lactic acid | Ambeed | 79-33-4 | MFCD00064266 | 90.078 | C3H6O3 | 85.000 | C[C@H](O)C(O)=O | 100g | 490510430